adenosine injection, solution
heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection, usp is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: - second- or third-degree av block (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker) [see warnings and precautions (5.2)] - known or suspected bronchoconstrictive or bronchospastic lung disease (e.g., asthma) [see warnings and precautions (5.3)] - known hypersensitivity to adenosine [see warnings and precautions (5.7)] pregnancy category c. animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if cle
adenosine baxter
baxter healthcare ltd - adenosine 3 mg/ml; ; - solution for infusion - 30 mg/10ml - active: adenosine 3 mg/ml excipient: sodium chloride water for injection - intravenous adenosine baxter 30 mg/10 ml is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging, in patients unable to exercise adequately.
adenosine injection, solution
physicians total care, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated for the following. conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning arti
aj-adenosine solution
agila jamp canada inc - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics
aj-adenosine solution
agila jamp canada inc - adenosine - solution - 3mg - adenosine 3mg - class iv antiarrythmics
adenosine injection, solution
hospira, inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - adenosine injection is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. adenosine injection is contraindicated in patients with: animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. because it is not known whether adenosine injection can cause fetal harm when administered to pregnant women, adenosine injection should be used during pregnancy only if clearly needed. it is not known whether adenosine injection is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions from adenosine injection in nursing infants, the decision to interrupt nursing after administration of adenosine injection or not to administer adenosine injection, should take into account the importance of the drug to the mother. the safety and effectiveness of adenosine injection in patients less than 18 years of age have not been established. clinical studies with adenosine injection did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently. other reported experience has not revealed clinically relevant differences of the response of elderly in comparison to younger patients.
adenosine 3mg/ml solution for injection
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - adenosine - solution for injection - adenosine 3 mg/ml - cardiac therapy
adenosine 3mg/ml solution for injection
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - adenosine - solution for injection - adenosine 3 mg/ml - cardiac therapy
adenosine 3mg/ml solution for injection
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - adenosine - solution for injection - adenosine 3 mg/ml - cardiac therapy
adenosine injection
hikma pharmaceuticals usa inc. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 3 mg in 1 ml - intravenous adenosine injection is indicated for the following: conversion to sinus rhythm of paroxysmal supraventricular tachycardia (psvt), including that associated with accessory bypass tracts (wolff-parkinson-white syndrome). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver), should be attempted prior to adenosine administration. it is important to be sure the adenosine solution actually reaches the systemic circulation (see dosage and administration ). adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. in the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. intravenous adenosine injection is contraindicated in: - second- or third-degree a-v block (except in patients with a functioning artificial pacemaker). - sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patient